Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
24
KTTA Quote, Financials, Valuation and Earnings
Last price:
$0.74
Seasonality move
:
-5.84%
Day range:
$0.71 - $0.78
52-week range:
$0.28 - $3.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.44x
Volume:
327.2K
Avg. volume:
217.6K
1-year change:
-66.12%
Market cap:
$5.4M
Revenue:
--
EPS (TTM):
-$5.08
Analysts' Opinion
-
Consensus RatingPasithea Therapeutics Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.00, Pasithea Therapeutics Corp. has an estimated upside of 313.79% from its current price of $0.73.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $0.73.
Fair Value
-
According to the consensus of 1 analyst, Pasithea Therapeutics Corp. has 313.79% upside to fair value with a price target of $3.00 per share.
KTTA vs. S&P 500
-
Over the past 5 trading days, Pasithea Therapeutics Corp. has underperformed the S&P 500 by -15.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Pasithea Therapeutics Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pasithea Therapeutics Corp. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Pasithea Therapeutics Corp. reported revenues of --.
Earnings Growth
-
Pasithea Therapeutics Corp. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Pasithea Therapeutics Corp. reported earnings per share of -$0.41.
Enterprise value:
1.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.10x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$667.3K
Return On Assets:
-84.34%
Net Income Margin (TTM):
--
Return On Equity:
-92.48%
Return On Invested Capital:
-91.9%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$492.3K | -$649K | -$667.3K | -$162.3K | -$181.5K | |
| Operating Income | -$14.9M | -$16.1M | -$13.9M | -$3M | -$3.1M | |
| EBITDA | -$14.4M | -$15.5M | -$13.2M | -$2.8M | -$2.9M | |
| Diluted EPS | -$12.40 | -$15.13 | -$5.08 | -$2.87 | -$0.41 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $21M | $44.5M | $20.8M | $9.8M | $5.5M | |
| Total Assets | $21M | $49.6M | $30.7M | $18.6M | $13.6M | |
| Current Liabilities | $528.1K | $1.5M | $2M | $660.4K | $1.4M | |
| Total Liabilities | $4.6M | $2.8M | $2.3M | $824K | $1.4M | |
| Total Equity | $16.5M | $46.8M | $28.4M | $17.8M | $12.2M | |
| Total Debt | -- | $724.4K | $210.8K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$14.1M | -$14.8M | -$12.3M | -$3.1M | -$2.9M | |
| Cash From Investing | -$1.9M | $54.5K | -- | -- | -- | |
| Cash From Financing | -$6.9M | $4.5M | $7.1M | $4.5M | -$116.1K | |
| Free Cash Flow | -$14.2M | -$14.8M | -$12.3M | -$3.1M | -$2.9M | |
KTTA
Sector
Market Cap
$5.4M
$23.4M
Price % of 52-Week High
19.13%
48.49%
Dividend Yield
0%
0%
Shareholder Yield
-137.51%
-1.67%
1-Year Price Total Return
-66.12%
-23.18%
Beta (5-Year)
--
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.82
200-day SMA
Sell
Level
$0.87
Bollinger Bands (100)
Sell
Level
0.66 - 1.06
Chaikin Money Flow
Sell
Level
-542.8K
20-day SMA
Sell
Level
$0.87
Relative Strength Index (RSI14)
Sell
Level
26.66
ADX Line
Sell
Level
14.07
Williams %R
Buy
Level
-95.0835
50-day SMA
Sell
Level
$0.99
MACD (12, 26)
Buy
Level
0.22
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Sell
Level
-493.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.7259)
Sell
CA Score
(Annual)
Level (-1.6516)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (19.8099)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Lawrence J. Steinman on May 12, 2020 and is headquartered in Miami Beach, FL.
Stock Forecast FAQ
In the current month, KTTA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KTTA average analyst price target in the past 3 months is $3.00.
-
Where Will Pasithea Therapeutics Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pasithea Therapeutics Corp. share price will rise to $3.00 per share over the next 12 months.
-
What Do Analysts Say About Pasithea Therapeutics Corp.?
Analysts are divided on their view about Pasithea Therapeutics Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pasithea Therapeutics Corp. is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Pasithea Therapeutics Corp.'s Price Target?
The price target for Pasithea Therapeutics Corp. over the next 1-year time period is forecast to be $3.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KTTA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pasithea Therapeutics Corp. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of KTTA?
You can purchase shares of Pasithea Therapeutics Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pasithea Therapeutics Corp. shares.
-
What Is The Pasithea Therapeutics Corp. Share Price Today?
Pasithea Therapeutics Corp. was last trading at $0.74 per share. This represents the most recent stock quote for Pasithea Therapeutics Corp.. Yesterday, Pasithea Therapeutics Corp. closed at $0.73 per share.
-
How To Buy Pasithea Therapeutics Corp. Stock Online?
In order to purchase Pasithea Therapeutics Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get KTTA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KTTA
Sector
P/E ratio
--
23.40x
PEG ratio
--
-0.01x
P/B ratio
0.44x
1.74x
Price / LTM sales
--
1.48x
Growth Metrics
KTTA
Sector
Revenue growth
--
3.36%
Earnings growth
85.8%
9.35%
Revenue (5-year growth)
--
6.22%
Earnings forecast
-$0.18
-$0.19
Profitability
KTTA
Sector
Profitability FY 2024
-$649K
$2.7M
Return on invested capital
-91.9%
-33.62%
Return on assets
-84.34%
-29.68%
Return on equity
-92.48%
-38.98%
Earnings Date
Last Earnings Date
Feb
8
Next Earnings Date
Feb
8
Estimated Next Earnings Date
May
10
Balance Sheet
KTTA
Sector
Total cash
$4.2M
$25M
Short term investments
--
$23.9M
Total assets
$16.1M
$72.5M
Long term debt
--
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
